Login / Signup

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

Rens BrasterSimran GrewalRemco VisserHelga K EinarsdottirMarjolein van EgmondGestur VidarssonMarijn Bögels
Published in: PloS one (2017)
In conclusion, human IgG3 does not have improved therapeutic efficacy compared to human IgG1 in a mouse tumour model.
Keyphrases
  • endothelial cells
  • pluripotent stem cells
  • type diabetes
  • young adults
  • adipose tissue
  • high fat diet induced
  • childhood cancer